Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S says FDA approves Novoseven RT for treatment of Glanzmann'S Thrombasthenia-Reuters


Monday, 7 Jul 2014 01:50pm EDT 

Novo Nordisk A/S:FDA approves Novoseven RT for the treatment of Glanzmann'S Thrombasthenia (GT) with refractoriness-Reuters.Novoseven RT also is approved in the European Union for the treatment of bleeding episodes in patients with GT.